I'm on a GLP-1 — What Other Peptides Do People Add?

The pattern: GLP-1 first, then "what else is out there?"

A common pattern over the last two years: someone starts on a GLP-1 agonist (semaglutide or tirzepatide) for weight loss. They lose 30+ pounds. They feel better. The injections become routine. And then they start asking — "what other peptides are people using? What about for recovery? Sleep? Skin? Longevity?"

GLP-1 normalized injections. The psychological barrier of self-injection — the thing that kept peptides confined to bodybuilding circles for two decades — has been removed for a much wider population. Once that barrier is gone, the question "what else?" follows naturally.

This article is for that moment. It is not a recommendation to start any particular compound. It's a map of what the broader peptide landscape looks like so you can have an informed conversation with your prescribing provider.

What's in the broader peptide landscape

Most of these are not FDA-approved as finished drugs and are obtained through compounding pharmacies or research-only suppliers. Each has different evidence bases, regulatory status, and risk profiles.

The most common stack additions for GLP-1 users

1. BPC-157 — for body recomposition support

Why people add it: GLP-1-driven weight loss can include lean mass loss (~25–30% of total weight lost is non-fat tissue per SURMOUNT-1 / STEP-1 data). Users pursuing body recomposition often add BPC-157 specifically to support recovery from increased training intensity.

Cadence change: GLP-1 is weekly; BPC-157 is daily. This adds tracking complexity. See the BPC-157 reconstitution guide.

2. CJC-1295 / Ipamorelin — for sleep and body composition

Why people add it: GH secretagogues stimulate endogenous GH release, which is anabolic for lean tissue and supports fat oxidation. Mechanistically complementary to GLP-1's primary appetite-suppression mechanism.

Critical timing detail: CJC-1295/Ipamorelin requires fasted-state injection (insulin suppresses GH pulse). GLP-1s have no such requirement. See the Ipamorelin timing guide.

3. TB-500 — paired with BPC-157

Rarely added solo; almost always paired with BPC-157 as a recovery stack. Different mechanism (actin sequestration, angiogenesis) but commonly co-administered. Twice-weekly cadence vs. daily BPC-157. See the recovery stack protocol guide.

Why tracking gets harder fast

You added one peptide to your weekly GLP-1. Now you're managing:

• Two compounds with different half-lives (weeks-long vs. hours)
• Two dosing cadences (weekly vs. daily)
• Two reconstitution setups (different vials, different bac water volumes)
• Two injection site rotations (more daily injections = more sites needed)
• Possibly two timing requirements (fasted state for some compounds)

A spreadsheet or notes app handles one compound. Two compounds is workable. Three compounds is where most users break down — the protocol exceeds working memory and starts producing missed doses, dose calculation errors, and inadequate site rotation. See the multi-compound tracking guide.

What to discuss with your provider before adding anything

Switching from GLP-1-only to a multi-compound protocol is a clinical decision, not a self-care choice. Questions to bring to your prescribing provider:

• Are there any contraindications between my current GLP-1 dose and the compound I'm considering adding?
• What's the source — is the compound from a licensed compounding pharmacy or research-only supplier?
• What's the rationale for adding it given my specific goals?
• What are the monitoring parameters — labs, side effects, what to watch for?
• What is the protocol exit plan — when do we reassess or stop?

The honest reality check

Most peptides outside GLP-1 agonists lack large randomized clinical trials in humans. Animal data is often promising, but extrapolation to human protocols is exactly that — extrapolation. Long-term safety data is limited. This doesn't mean they don't work or are dangerous; it means the evidence base is thinner than for GLP-1 drugs (which have decade-plus trial data).

Going from a well-studied GLP-1 to an additional compound that lacks human Phase 3 trial data is a meaningful change in your risk profile. That's a decision for you and your provider — informed, not casual.

If you do add a compound: track it properly from day one

The most common mistake is starting a second compound on top of GLP-1 without changing tracking infrastructure. Your existing notes/calendar approach was barely working for a single weekly drug — adding a second drug to the same system breaks down within weeks.

My Pep Calc was built specifically for the multi-compound case: each compound has its own log, dose history, half-life curve, and site rotation tracking. The half-life chart shows your full protocol on one timeline so you and your provider can see what's actually happening.